Article

542 Recovery of Right Heart Function with Temporary Right Ventricular Assist Using a Centrifugal Pump in Patients with Severe Biventricular Failure

Department of Cardiovascular Surgery, Osaka University Graduate School of Medicine, Suita, Osaka, Japan.
The Journal of heart and lung transplantation: the official publication of the International Society for Heart Transplantation (Impact Factor: 5.61). 05/2012; 31(8):858-64. DOI: 10.1016/j.healun.2012.03.002
Source: PubMed

ABSTRACT Long-term outcomes of a biventricular assist device (BiVAD) support are worse than those of an isolated left ventricular assist device (LVAD) support. This study evaluated our strategy for right heart failure using a temporary right VAD (RVAD) with an extracorporeal centrifugal pump.
From January 2001 to December 2010, 108 patients underwent LVAD implantation at our institution and their clinical outcomes were studied.
A temporary centrifugal RVAD was implanted in 26 patients. Multivariate logistic regression revealed pre-operative extracorporeal life support (odds ratio [OR], 37.0), central venous pressure (OR, 1.2), mean pulmonary artery pressure (OR, 0.9), and serum total bilirubin (OR, 1.4) were the risk factors for RVAD requirement. RVAD-off test was conducted, and 11 of the 26 patients showed significant recovery of right heart function and were eventually removed from RVAD support. The survival of patients with isolated LVAD was significantly better than those with a paracorporeal pulsatile BiVAD (80% vs 11% at 1 year, p < 0.001). However, there was no significant difference between the survival of patients who underwent isolated LVAD support and those who were initially implanted with temporary BiVAD but underwent the RVAD removal (80% vs 73% at 1 year, p = 0.827).
Our strategy with temporary RVAD for severe acute right heart failure was effective in selecting the patients who could be weaned from RVAD support. Patient survival was improved by avoiding the long-term support with a paracorporeal pulsatile BiVAD.

0 Followers
 · 
102 Views
 · 
0 Downloads
  • [Show abstract] [Hide abstract]
    ABSTRACT: OBJECTIVE: Right heart failure is a major cause of morbidity and mortality after left ventricular assist device (LVAD) implantation. This study evaluated the approach of a cavoaortic shunt included in the LVAD circuit, which would aim to relieve venous congestion and improve hemodynamics with preserved oxygen delivery during induced right ventricular failure. METHODS: Right ventricular failure was induced by coronary ligation in 10 pigs. An LVAD was implanted and a cavoaortic shunt was created from the right atrium and included in the assist circuit. Hemodynamic measures and blood gas analyses were analyzed. Oxygen delivery and oxygen consumption were estimated. RESULTS: Right atrial pressure decreased from more than 20 mm Hg to 17.2 mm Hg (14.8-18.4) with the LVAD and to 14.1 mm Hg (11.2-15.5) (P < .01) with the LVAD and cavoaortic shunt. Mean arterial pressure increased from 70.9 mm Hg (67.6-79.8) to 81.5 mm Hg (70.8-92.6) (P = .02) with addition of the shunt into the assist circuit. Cardiac output increased from 3.5 L/min (2.6-4.2) to 4.9 L/min (3.5-5.6) (P < .01) with cavoaortic shunting. Oxygen delivery with the cavoaortic shunt was 337 mL/min (±70) as compared with left ventricular assist alone at 258 mL/min (±52) (P < .01). Oxygen consumption was restored during use of the cavoaortic shunt. CONCLUSIONS: A cavoaortic shunt combined with an LVAD during right ventricular failure reduces central venous pressures, increases systemic arterial pressure, and enables increased cardiac output compared with device therapy alone. This was feasible with preserved oxygen delivery.
    The Journal of thoracic and cardiovascular surgery 03/2013; 147(2). DOI:10.1016/j.jtcvs.2013.02.010 · 3.99 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: Background: The DuraHeart left ventricular assist device (LVAD) is the world's first approved magnetically levitated implantable centrifugal pump. We report our initial experience with the DuraHeart as a bridge to heart transplantation. Methods and Results: Between 2008 and 2011, 23 patients (17 males; mean age 35 years, range 16-53 years) with endstage heart failure underwent implantation with the DuraHeart LVAD at Osaka University Hospital. Of those, 7 underwent conversion surgery from a Nipro paracorporeal LVAD to the DuraHeart. There were no deaths during the mean support period of 559±241 days (176-999 days). In total, 17 patients (74%) remain with the LVAD and 5 (22%) underwent heart transplantation after 580±302 days (176-982 days) of support. Major adverse events included 8 (34%) driveline/pocket infections, 4 (17%) cerebrovascular accidents, 4 (17%) right heart failures requiring mechanical support, and 3 (13%) mechanical device failures (magnetic levitation failure caused by driveline fracture). Of the 5 patients who developed pump pocket infection, 3 underwent previous conversion surgery from the Nipro LVAD. Conclusions: Our initial experience with the DuraHeart LVAD in Japan demonstrated excellent long-term survival with acceptable rates of adverse events. With refinement of the system, including mechanical durability, this pump will further enhance the quality of life for patients who require long-term mechanical circulatory support.
    Circulation Journal 04/2013; 77(7). DOI:10.1253/circj.CJ-12-1410 · 3.69 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: BACKGROUND: There are an increasing number of elderly patients with end-stage heart failure. Destination mechanical circulatory support is often the only therapy available for these patients who are not transplant candidates. The outcomes after continuous flow left ventricular assist device (CF LVAD) implant in older patients remains unclear. We undertook this multi-institutional study to quantify short-term and midterm outcomes after CF LVAD implant in the elderly. METHODS: We retrospectively analyzed all patients in the Interagency Registry for Mechanically Assisted Circulatory Support (INTERMACS) national registry that underwent implant of a CF LVAD (June 2006 to April 2012). Patients were divided into 2 cohorts based upon age (<70 years [n = 4,439] and ≥70 years (n = 590]). Preoperative, intraoperative, and postoperative variables were analyzed. The primary endpoint, survival, was compared between cohorts. RESULTS: Patients age 70 and older were more hemodynamically stable pre-VAD implant as evidenced by INTERMACS profile and inotrope dependence. Perioperative outcomes, including median bypass time (89 vs 89 minutes) and length of stay (0.657 vs 0.657 months) were similar between cohorts (p = not significant). Kaplan-Meier analysis revealed a significant difference in 2-year survival between patients aged 70 years or greater (63%) and less than 70 (71%, p < 0.001). Multivariable Cox proportional hazard analysis revealed age as an independent predictor of mortality during follow-up (p < 0.001). Nonetheless, midterm cumulative survival in the older cohort was still reasonable (63% at 2 years). CONCLUSIONS: Multi-institutional analysis revealed advanced age as a predictor of increased mortality after CF LVAD implantation. Careful patient selection is critical in the elderly to optimize long-term outcomes after CF LVAD implantation.
    The Annals of thoracic surgery 05/2013; 96(1). DOI:10.1016/j.athoracsur.2013.04.010 · 3.65 Impact Factor
Show more